SecBot SecBot
PRESS-RELEASE ·Filed Jun 1, 2026

IRON

Disc Medicine Inc
NEUTRAL
Impact 4/10
Horizonmonths Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

The EAP launch is a modest positive for patient access optics but does not derisk APOLLO. Key binary catalyst is APOLLO topline data in Q4 2026; the mid-2027 FDA decision timeline reinforces that near-term stock movement will be driven by Phase 3 results, not today's announcement. Traders should focus on APOLLO enrollment and data timing updates.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$71.97
T+0 close · Jun 1, 2026 · via day close
Latest settled
+14.51%
T+60 · $82.41
Vs SPY
+13.27%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 1 $71.97entry
  2. T+1 · 6mo ago −5.52%α −5.66% · $68.00
  3. T+5 · 5mo ago −6.91%α −4.16% · $67.00
  4. T+20 · 5mo ago +1.63%α +2.92% · $73.14
  5. T+60 · 3mo ago +14.51%α +13.27% · $82.41
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Disc Medicine launched an expanded access program (EAP) for bitopertin in erythropoietic protoporphyria (EPP)/X-linked protoporphyria (XLP) patients in the U.S., while noting that Phase 3 APOLLO topline data is expected in Q4 2026, with a CRL response and FDA decision expected by mid-2027. This is a procedural step that does not change the binary risk/reward of the upcoming Phase 3 readout and regulatory decision, and does not add new safety/efficacy data.

Key Facts

  • EAP launched for bitopertin in eligible EPP/XLP patients aged 12+ in the U.S.
  • Phase 3 APOLLO double-blind, placebo-controlled trial ongoing; topline data expected Q4 2026
  • Disc Medicine expects to submit a CRL response with FDA decision by mid-2027
  • Bitopertin is not approved in any jurisdiction; an earlier CRL prompted the updated timeline
  • Company market cap ~$2.7B; analyst consensus is heavily bullish (95% buy-side)

Financial Impact

No financial data provided in this press release; the EAP is a non-revenue-generating program

Risk Factors

  • Phase 3 APOLLO may fail to meet primary endpoint, as bitopertin previously received a CRL
  • CRL response may be rejected by FDA, delaying or preventing approval beyond mid-2027
  • EAP access does not guarantee favorable regulatory outcome or commercial adoption
  • High cash burn for clinical-stage biotech with no approved products

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3304352

Track record

43 reports on IRON

Performance horizon

7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +20.07% at T+20 after the Sep 3, 2026 report. 11 of 16 went positive at some point.

Filters
  1. Nov 10, 20266d ago 144 Neutral 2/10 Entry $87.08 Now $76.59 −12.05% settles Dec 10
  2. Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $78.91 Now $76.59 +2.94% settles Dec 7
  3. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  4. Nov 5, 202611d ago Press Release Bullish 7/10 Entry $78.47 Now $76.59 −2.40% settles Dec 4
  5. Nov 4, 202612d ago Press Release Neutral 3/10 Entry $83.28 Now $76.59 −8.03% settles Dec 3
  6. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $81.16 Now $76.59 −5.63% settles Dec 2
  7. Oct 26, 202621d ago SC 13D/A Neutral 3/10 Entry $79.90 Now $76.59 −4.14% settles Nov 24
  8. Oct 22, 202625d ago 8-K Bearish 6/10 Entry $74.51 Now $76.59 −2.79% settles Nov 20
  9. Oct 21, 202626d ago 424B5 Bearish 6/10 Entry $75.03 Now $76.59 −2.08% settles Nov 19
  10. Oct 21, 202626d ago 144 Neutral 2/10 Entry $75.03 Now $76.59 +2.08% settles Nov 19
Showing 10 of 43

US Market Status

Market Closed · Opens Wed (9h 52m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 1, 2026